Last $57.43 USD
Change Today +1.08 / 1.92%
Volume 89.6K
CPHD On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 11:32 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

cepheid inc (CPHD) Snapshot

Open
$56.60
Previous Close
$56.35
Day High
$58.08
Day Low
$56.60
52 Week High
02/17/15 - $59.68
52 Week Low
07/31/14 - $36.94
Market Cap
4.1B
Average Volume 10 Days
335.3K
EPS TTM
$-0.43
Shares Outstanding
71.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEPHEID INC (CPHD)

cepheid inc (CPHD) Related Businessweek News

No Related Businessweek News Found

cepheid inc (CPHD) Details

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample; and GeneXpert Infinity System for high volume testing. The company sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; Life Technologies Corporation to develop reagents for use in the USPS BDS program; AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, and others to develop Xpert Carba-R, a rapid diagnostic test; and Paul G. Allen Family Foundation and the BMGF to develop Xpert Ebola, a rapid test that. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

1,400 Employees
Last Reported Date: 02/26/15
Founded in 1996

cepheid inc (CPHD) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $577.2K
President of Hbdc
Total Annual Compensation: $433.5K
Chief Regulatory Officer and Executive Vice P...
Total Annual Compensation: $352.5K
Compensation as of Fiscal Year 2013.

cepheid inc (CPHD) Key Developments

Cepheid Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-04-2015 10:25 AM

Cepheid Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-04-2015 10:25 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States.

Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test

Cepheid announced it has received clearance from the U.S. Food & Drug Administration (FDA) for expanded claims on its Xpert® MTB/RIF test. Xpert MTB/RIF detects Mycobacterium tuberculosis complex (MTB-complex) DNA and in positive specimens, provides simultaneous identification of rifampin-resistance associated mutations of the rpoB gene. The expanded product claim enables clinicians to use either one or two negative Xpert MTB/RIF test results, in conjunction with other clinical and laboratory data, to remove patients from airborne infection isolation (AII), commonly referred to as respiratory isolation. The test runs on the Cepheid GeneXpert® System, the molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.

Cepheid Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter of 2015 and Fiscal Year Ending December 31, 2015

Cepheid announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. The company reported revenue for the fourth quarter of 2014 of $131.5 million. Net loss was $23.8 million, or $0.34 per share, which compares to revenue of $113.3 million and net loss of $10.3 million, or $0.15 per share, in the fourth quarter of 2013. 2014 fourth quarter net loss included a legal contingency charge of $20 million, or $0.28 per share. Excluding stock compensation expenses, a legal contingency charge, amortization of debt discount and transaction costs, and amortization of purchased intangible assets, non-GAAP net income for the fourth quarter of 2014 was $7.8 million, or $0.11 per share. This compares to non-GAAP net income of $2.3 million, or $0.03 per share, for the fourth quarter of 2013, which excluded stock compensation expenses, a restructuring charge (including impairment of certain assets), and amortization of purchased intangible assets. Loss from operations was $18.804 million against $9.905 million a year ago. Non-GAAP income from operations was $10.340 million against $2.950 million a year ago. For the year ended December 31, 2014, the company reported revenue of $470.1 million which compares to revenue of $401.3 million in 2013. Net loss for the year was $50.1 million, or $0.72 per share, which compares to net loss of $18.0 million, or $0.27 per share, in 2013. 2014 full year net loss included a legal contingency charge of $20 million, or $0.29 per share. Excluding stock compensation expenses, a legal contingency charge, amortization of debt discount and transaction costs, and amortization of purchased intangible assets, non-GAAP net income for the full year 2014 was $14.2 million, or $0.19 per share. This compares to a non-GAAP net income of $17.9 million, or $0.26 per share, for the full year 2013, which excluded stock compensation expenses, a restructuring charge (including impairment of certain assets), and amortization of purchased intangible assets. Loss from operations was $34.086 million against $16.010 million a year ago. Net cash provided by operating activities was $9.194 million against $15.012 million a year ago. Capital expenditures were $46.979 million against $47.526 million a year ago. Non-GAAP income from operations was $21.678 million against $20.123 million a year ago. For the fiscal year ending December 31, 2015, the company expects total revenue to be in the range of $538 to $553 million; net loss in the range of $0.55 to $0.51 per share; non-GAAP net income in the range of $0.19 to $0.23 per share. Expected non-GAAP net income excludes approximately $37 million related to stock compensation expense, approximately $10 million related to the amortization of debt discount and transaction costs, and approximately $6 million related to the amortization of purchased intangible assets. The company expects non-GAAP gross margin to improve due to continued progress in the initiatives in operations, but for this to be offset in part by FX since the strengthening of the U.S. dollar not only impacts revenue but also negatively impacts gross margin given that the majority of the commercial revenue is manufactured in the U.S. As a result, despite a 70 basis point headwind from currency, still the company expects non-GAAP gross margin to expand by 80 basis points to a figure that rounds down to 53%. The company expects a similar improvement in commercial gross margin, which expects to round down to 62%. For the full year, the company expects operating expenses to increase just under $50 million. As a result, the company expects its 2015 non-GAAP operating margin to be about the same as the 4.6% of revenue reported in 2014. Looking at the first quarter of 2015 and after the record-breaking fourth quarter with particular strength in commercial Clinical systems due to seasonality, the company expects total first quarter revenue to range from $123 million to $126 million. The company expects commercial Clinical revenue to be down modestly on a sequential basis ranging between $100 million and $102 million, with a decline in commercial Clinical system revenue offset in part by continued growth in commercial Clinical reagent revenue. Overall, this represents expected growth of between 22% and 24% from the first quarter of 2014. The company expects HBDC revenue in the range of $17 million to $18 million, and the company expects Non-Clinical revenue of approximately $6 million. Non-GAAP operating expenses are expected to increase in the $2 million to $3 million range from the fourth quarter 2014. The company expects first quarter net income to range from a loss of $0.01 to income of $0.01 per share on a non-GAAP basis and a loss per share of between $0.19 and $0.17 on a GAAP basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPHD:US $57.43 USD +1.08

CPHD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Luminex Corp $15.86 USD -0.03
Meridian Bioscience Inc $19.97 USD -0.09
QIAGEN NV €22.78 EUR +0.459
Quidel Corp $26.22 USD +0.27
Sequenom Inc $3.76 USD +0.105
View Industry Companies
 

Industry Analysis

CPHD

Industry Average

Valuation CPHD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.5x
Price/Book 11.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEPHEID INC, please visit www.cepheid.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.